Glenmark Pharmaceuticals Limited, together with its subsidiaries, develops, manufactures, and markets pharmaceutical products in India, North America, Latin America, Europe, and internationally. The company provides branded and generic formulations in therapeutic areas of dermatology, respiratory, and oncology; and various active pharmaceutical ingredients. Its product pipeline includes ISB 830, an OX40 antagonist monoclonal antibody, which is in Phase 2b clinical trial for the treatment of atopic dermatitis; ISC 17536, an oral transient receptor potential ankyrin-1 antagonist, which has completed Phase 2a clinical trial for the treatment of diabetic peripheral neuropathy; ISB 1302, a HER2 X CD3 beat bispecific antibody, which is in Phase 1/2 clinical trial for the treatment of metastatic HER2-positive breast cancer; and ISB 1342, a CD38 X CD3 beat bispecific antibody that is in Phase 1 clinical trial for the treatment of relapsed/refractory multiple myeloma. The company's pre-clinical stage product pipeline comprises ISB 880 for the for the treatment of anti-inflammatory therapy; ISB 1908 and ISB 1909 T-cell engagers for the treatment of oncology; ISB 1442, an innate immune engager for the treatment of oncology; ISC XXXXX, an HPK1 inhibitor for the treatment of oncology; and GRC 39815, an inhibitor of the retinoid-related orphan receptor gamma t for the treatment of chronic obstructive pulmonary disorder. It also offers Ryaltris nasal spray for allergic rhinitis. The company was founded in 1977 and is based in Mumbai, India. The ISIN of this stock is INE935A01035.